Clinical analysis of 50 children with juvenile dermatomyositis

Modern Rheumatology

Volumn 23, Issue 2, 2013, Pages 311-317

  Kishi, Takayuki ^a   Miyamae, Takako ^b   Hara, Ryoki ^b   Nakajima, Shoko ^b   Imagawa, Tomoyuki ^b   Mori, Masaaki ^b   Yokota, Shumpei ^b  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Calcinosis; Cyclophosphamide; Immunoglobulin E; Interstitial pneumonia; Juvenile dermatomyositis

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISOLONE;

ADOLESCENT; ARTICLE; CHILD; DERMATOMYOSITIS; FEMALE; HUMAN; INFANT; INTERSTITIAL LUNG DISEASE; MALE; ONSET AGE; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; AGE OF ONSET; ANTI-INFLAMMATORY AGENTS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DERMATOMYOSITIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LUNG DISEASES, INTERSTITIAL; MALE; METHYLPREDNISOLONE; PREDNISOLONE; TREATMENT OUTCOME;

EID: 84879006280     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0647-4     Document Type: Article

References (32)

1. Cassidy JT, Lindsley CB. Juvenile Dermatomyositis. In: Cassidy JT, Petty RE, editors. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Elsevier Saunder; 2010. p. 375-413.
2. Spencer-Green G, Schlesinger M, Bove KE, Levinson JE, Schaller JG, Hanson V, et al. Nailfold capillary abnormalities in childhood rheumatic diseases. J Pediatr. 1983;102: 341-6.
3. Rider LG, Atkinson JC. Images in clinical medicine. Gingival and periungual vasculopathy of juvenile dermatomyositis. N Engl J Med. 2009;360:e21.
4. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 2000;43: 541-9.
5. Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol. 2002;47: 505-11.
6. Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. 2001;164: 1182-5.
7. Lee CS, Chen TL, Tzen CY, Lin FJ, Peng MJ, Wu CL, et al. Idiopathic inflammatory myopathy with diffuse alveolar damage. Clin Rheumatol. 2002;21: 391-6.
8. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292: 344-7.
9. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292: 403-7.
10. Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, Pachman LM: NIAMS Juvenile DM Registry Physician Referral Group. US incidence of juvenile dermatomyositis. 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003;49: 300-5.
11. Pachman LM, Hayford JR, Hochberg MC, Pallansch MA, Chung A, Daugherty CD, et al. New-onset juvenile dermatomyositis: comparisons with a healthy cohort children with juvenile rheumatoid arthritis. Arthritis Rheum. 1982;25: 126-39.
12. Fujikawa S, Okuni M. A nationwide surveillance study of rheumatic diseases among Japanese children. Acta Pediatr Jpn. 1997;39: 242-4.
13. Paller AS. Juvenile dermatomyositis and overlap syndromes. Adv Dermatol. 1995;10: 309-27.
14. Crowe WE, Bove KE, Levinson JE, Hilton PK. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum. 1982;25: 126-39.
15. Read AM, Pachman LM, Hayford J, Ober C. Immunogenetic studies in families of children with juvenile dermatomyositis. J Rheumatol. 1998;25: 1000-2.
16. Guzman J, Petty RE, Malleson PN. Monitoring disease activity in juvenile dermatomyositis: the role of von Willebrand factor and muscle enzymes. J Rheumato. 1994;21: 739-43.
17. Bowyer SL, Ragsdale CG, Sullivan DB. Factor VIII related antigen and childhood rheumatic diseases. J Rheumatol. 1989;16: 1093-7.
18. Bloom BJ, Tucker LB, Miller LC, Schaller JG. Von Willebrand factor in juvenile dermatomyositis. J Rheumatol. 1995;22: 320-5.
19. Harden LM, du Plessis I, Poole S, Laburn HP. Interleukin (IL)-6 and IL-1 beta act synergistically within the brain to induce sickness behavior and fever in rats. Brain Behav Immun. 2008;22:838-49 (Epub 5 Feb 2008).
20. MacNamara KC, Oduro K, Martin O, Jones DD, McLaughlin M, Choi K, et al. Infection-induced myelopoiesis during intracellular bacterial infection is critically dependent upon IFN-c signaling. J Immunol. 2011;186:1032-43 (Epub 13 Dec 2010).
21. Nishikawa T, Hagihara K, Serada S, Isobe T, Matsumura A, Song J, et al. Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression. J Immunol. 2008;180: 3492-501.
22. Elst EF, Klein M, de Jager W, Kamphuis S, Wedderburn LR, van der Zee R, et al. Hsp60 in inflamed muscle tissue is the target of regulatory autoreactive T cells in patients with juvenile dermatomyositis. Arthritis Rheum. 2008;58: 547-55.
23. Hiketa T, Ohashi M, Matsumoto Y, Morikawa J, Sasaki R. Elevated serum immunoglobulin E levels in patients with juvenile dermatomyositis. J Allergy Clin Immunol. 1992;90: 405-7.
24. Moore EC, Cohen F, Douglas SD, Gutta V. Staphylococcal infections in childhood dermatomyositis-association with the development of calcinosis, raised IgE concentrations and granulocyte chemotactic defect. Ann Rheum Dis. 1992;51: 378-83.
25. Schimke LF, Sawalle-Belohradsky J, Roesler J, Wollenberg A, Rack A, Borte M, et al. Diagnostic approach to the hyper-IgE syndromes: immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis. J Allergy Clin Immunol. 2010;126: 611-7.
26. Ramanan AV, Feldman BM. Clinical features and outcome of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am. 2002;28: 833-57.
27. Sallum AM, Pivato FC, Doria-Fiho U, Aikawa NE, Liphaus BL, Marie SK, et al. Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr. 2008;84: 68-74.
28. Kim S, El-Gallak M, Degeoglu F, Zurakowski D, Fuhlbrigge RC, Sundel RP, et al. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum. 2009;60: 1825-30.
29. Huber AM, Lang B, LeBlank CM, Birdi N, Bolaria RK, Malleson P, et al. Medium- and long term functional outcome in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 2000;43: 541-9.
30. Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, et al. Childhood Myositis Heterogeneity Study Group : Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore). 2008;87: 70-86.
31. Sanner H, Aaløkken TM, Gran JT, Sjaastad I, Johansen B, Flatø B. Pulmonary outcome in juvenile dermatomyositis: a case-control study. Ann Rheum Dis. 2011;70:86-91 (Epub 30 Aug 2010).
32. Parambil JG, Myers JL, Aubry MC, Ryu JH. Causes and prognosis of diffuse alveolar damage diagnosed on surgical lung biopsy. Chest. 2007;132:50-7 (Epub 2 May 2007).